Neurogenics logo
Population Health

From reactive healthcare to preventative health.

Our technology has an important role to play. Health systems were built around acute illness. The dominant burden is now chronic disease that develops over decades. Preventative and population health approaches aim to intervene earlier and reduce that long-term burden. This is critical in an age where the state no longer can afford the increasing financial burden of health care costs as populations age. The age of precision health care has arrived allowing us to predict, prevent, diagnose, and treat diseases more precisely. We are working with the Centre for Health Leadership & Enterprise (CCHLE) initiative and the Global Centre for Health Convergence, a joint global strategic initiative between Cambridge Judge Business School and Excite Ventures.

ESTABLISHED MODEL

Reactive care

  1. 01Disease
  2. 02Diagnosis
  3. 03Treatment
EMERGING MODEL

Preventative population health

  1. 01Risk identification
  2. 02Earlier intervention
  3. 03Nutrition, science and technology
  4. 04Monitoring
  5. 05Improved population health

Conceptual comparison of two care models. It describes a direction of travel in health policy and practice. It is not a claim about guaranteed outcomes.

Why the model must change

Chronic disease has changed the healthcare challenge.

43 million1

DEATHS A YEAR

Noncommunicable diseases account for roughly three quarters of deaths worldwide.

2.1 billion2

PEOPLE AGED 60 AND OVER BY 2050

Longer lives extend the period in which chronic conditions develop.

17.9 million3

CARDIOVASCULAR DEATHS A YEAR

Cardiovascular disease remains the leading single cause of death.

Economic impact

Diabetes is a health challenge with an economic consequence.

The burden of diabetes extends beyond prevalence. Treatment, long-term management and complications place substantial and growing demands on the NHS and the wider economy.7

£10.7bn

CURRENT ANNUAL NHS COST

Estimated annual cost of diabetes to the UK NHS.

£6.2bn

COST OF COMPLICATIONS

Approximately 60% of current NHS diabetes expenditure is associated with complications.

~£18bn

PROJECTED NHS COST BY 2035

Estimated annual NHS cost if diabetes prevalence continues to rise at the current rate.

£3.3bn

WIDER ECONOMIC IMPACT

Estimated annual costs from worklessness and premature mortality included in the economic analysis.

Source: Diabetes UK / York Health Economics Consortium, Investing in Diabetes Care.

These figures illustrate the scale of the economic challenge associated with diabetes. They do not represent potential savings attributable to Neurogenics, and Neurogenics currently makes no claim to prevent or treat diabetes.

The cardiometabolic challenge

Related conditions, one connected challenge.

Obesity, insulin resistance, prediabetes, type 2 diabetes and hypertension are interconnected components of a growing global cardiometabolic challenge. Together they contribute substantially to cardiovascular disease and reduced healthspan.4,5,6

  • Obesity + metabolic dysfunctionUPSTREAM
  • Insulin resistanceMECHANISM
  • Prediabetes · Type 2 diabetesOVERLAPPING
  • Hypertension · Cardiovascular diseaseDOWNSTREAM
  • Reduced healthspanOUTCOME

The relationships shown are interconnected, not an inevitable progression. Individual pathways vary. Nothing here is a treatment claim.

Prevention

Intervene earlier.

In the established model, risk becomes disease before the system responds. A preventative model works upstream of diagnosis.

  1. 01

    Risk identification

    Recognising elevated cardiometabolic risk earlier.

  2. 02

    Earlier intervention

    Acting before conditions become established.

  3. 03

    Ongoing support

    Sustained nutrition, lifestyle and clinical input.

  4. 04

    Monitoring

    Measurement over time rather than at a single appointment.

  5. 05

    Better management

    Care organised around long-term health, not episodes.

This describes a changing healthcare paradigm. No single company delivers it. Neurogenics does not.

Health is more than medicine

Population health is becoming a convergence.

Medical science increasingly sits alongside nutrition, diagnostics, monitoring, digital technology and behavioural support. The fields below are areas of activity across the sector. They are not Neurogenics capabilities.

Converging on

Population Health

  • MEDICAL SCIENCE
  • NUTRITION
  • DIAGNOSTICS
  • MONITORING
  • DIGITAL TECHNOLOGY
  • ARTIFICIAL INTELLIGENCE
  • BEHAVIOUR AND LIFESTYLE
Where Neurogenics fits

One technology component within a larger system.

Neurogenics has developed a flavanol technology platform. Its focus on characterised bioactive flavanols places the technology at the point where nutrition, medical foods, botanicals and health science meet.

We make no claim to prevent obesity, diabetes, hypertension or cardiovascular disease. Clinical evidence has not been established. What we can say is narrower and more useful: preventative population health will require characterised, manufacturable, evidence based components, and we are building one of them.

Any wording describing external institutional relationships is subject to approval. [CAMBRIDGE RELATIONSHIP WORDING TO BE APPROVED]

Nutrition
Everyday food as a route to sustained intake.
Medical foods
Standardised composition for defined dietary use.
Botanicals
Characterised plant derived bioactives.
Health science
Mechanistic and analytical evidence.
Future therapeutics
Regulated development, subject to clinical evidence.
Partnership model

Evidence is built with others, or not at all.

The pathway below is an intended route, not a record of achievements.

CONTRIBUTIONS

  • Neurogenics technology
  • University science
  • Clinical research
  • Population health expertise
  • Public and private partners

INTENDED PATHWAY

  1. 01Evidence
  2. 02Validation
  3. 03Scalability
  4. 04Potential population impact
Get in touch

Validation, research and partnership will determine what this platform becomes.

We are speaking with government, universities, research institutions, funders and industrial partners about clinical validation, evaluation and scale.

Get in touch

References

  1. 01World Health Organization. Noncommunicable diseases: fact sheet. WHO, 2024. Source
  2. 02World Health Organization. Ageing and health — fact sheet. WHO, Geneva. Source
  3. 03World Health Organization. Cardiovascular diseases (CVDs) — fact sheet. WHO, Geneva. Source
  4. 04World Health Organization. Obesity and overweight — fact sheet. WHO, 2024. Source
  5. 05International Diabetes Federation. IDF Diabetes Atlas, 11th edition. IDF, 2025. Source
  6. 06World Health Organization. Global report on hypertension: the race against a silent killer. WHO, 2023. Source
  7. 07Diabetes UK / York Health Economics Consortium. Investing in Diabetes Care. Diabetes UK, United Kingdom. Source